Day: July 28, 2022

A Hylink, que oferece publicidade de serviço completo por meio da sua prática de Travel + Travel Retail, a Hylink Travel, passará oferecer às marcas de viagens oportunidades e recursos exclusivos na plataforma Trip.com e Ctrip com esta parceria

LOS ANGELES, July 28, 2022 (GLOBE NEWSWIRE) — A Hylink Digital (Hylink), uma agência global de serviços completos premiada por 30 anos, foi escolhida a parceira estratégica oficial da Trip.com e da Ctrip para as Américas (América do Norte e do Sul). Esta é a primeira parceria deste tipo entre uma agência de publicidade e uma agência de viagens online internacional.

Com o retorno do turismo, os profissionais de marketing de destino, marcas de viagens e profissionais de marketing de viagens podem esperar mais lucros com seus serviços, além de tarifas melhores e acesso exclusivo ao estoque e à criação de conteúdo por meio dessa parceria.

“Sempre tivemos um relacionamento profundo com a Hylink, e essa parceria em particular é muito oportuna com o retorno das viagens em todo o mundo. Devemos ter uma recuperação total com as viagens em todo o mundo”, disse Edison Chen, Gerente Geral da Trip.com e da Ctrip Partnerships.

Neste ano histórico para viagens, é evidente que a indústria de viagens está mudando, e o futuro das viagens contará com parcerias como esta. “O modelo de negócios da Trip.com funciona em todos os setores relacionados às viagens, seja turismo de viagens, marketing de destino, varejo de viagens, saúde, educação ou marcas de viagens”, disse Humphrey Ho, sócio-gerente da Hylink Digital nas Américas.

Trip.com Group Limited
Website: https://us.trip.com/?locale=en_us
Facebook: https://www.facebook.com/Trip/
Instagram: https://www.instagram.com/trip/
Twitter: https://twitter.com/Trip/
WeChat: https://pages.trip.com/images/social-media/wechatQRCode.png
YouTube: https://www.youtube.com/c/TripOfficial

Hylink Digital
Website: https://hylinkgroup.com/
Instagram: https://www.instagram.com/hylinkdigital/?hl=en
Twitter: https://twitter.com/hylinkdigital
LinkedIn: https://fr.linkedin.com/company/hylink

Sobre o Trip.com Group
O Trip.com Group Limited, anteriormente Ctrip.com International, é uma empresa de viagens online multinacional chinesa que fornece serviços, incluindo reservas de estadias, passagens, pacotes de turismo e gestão de viagens corporativas.

Trip.com é uma empresa listada na NASDAQ desde 2003 (NASDAQ: TCOM) com mais de 1,4 milhões de hotéis em 200 países e regiões, e uma rede de voos de longo alcance de mais de 2 milhões de rotas que conectam mais de 5.000 cidades em todo o mundo. A agência estabeleceu uma extensa rede de hotéis e voos que oferece aos clientes diversas opções em todo o mundo.

Sobre a Hylink Digital Solutions
A Hylink Digital (Hylink) é uma agência de publicidade e comunicações internacional independente totalmente integrada, com mais de 20 escritórios em todo o mundo e sedes em Los Angeles, Califórnia e em Nova York nos Estados Unidos. Classificada como Agência Digital n^o 1 pela Revista Semanal China Internet (CI) durante 14 anos consecutivos entre 2008 e 2021. A Hylink também foi vencedora do prêmio Effie China durante vários anos como a Rede de Agências Independentes Mais Eficazes do Ano e foi identificada como uma agência de crescimento mais rápido pela Adweek em 2021. A Hylink Digital recebeu 32 prêmios no 2021 Interactive Creative & Media Marketing Awards (anteriormente Modern Advertising Awards).

A Hylink consiste em unidades líderes do setor nas seguintes áreas: mídia digital, criatividade interativa, programática, SEM, marketing e investimento de conteúdo, EPR/social, pesquisa e insights. A Hylink atende empresas da Fortune Global 500, tanto na sua sede da China quanto na dos EUA, e tem escritórios de apoio em todo o mundo. Para mais informação, visite www.hylinkgroup.com, ou siga a Hylink no LinkedIn ou Twitter em @hylinkdigital.

Contato com a Mídia: Alana Reid

Nome: Alana Reid

Email: alana.reid@hylinkgroup.com

NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Molecular Partners AG (NASDAQ: MOLN): (i) pursuant and/or traceable to the offering documents issued in connection with the Company’s initial public offering conducted on or about June 16, 2021 (the “IPO”); and/or (ii) between June 16, 2021 and April 26, 2022, both dates inclusive (the “Class Period”), of the important September 12, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Molecular Partners securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Molecular Partners class action, go to https://rosenlegal.com/submit-form/?case_id=7548 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 12, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the IPO documents were negligently prepared and, as a result, contained untrue statements of material fact or omitted to state other facts necessary to make the statements made not misleading and were not prepared in accordance with the rules and regulations governing their preparation. Additionally, the complaint alleges that, throughout the Class Period, defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, the IPO documents and defendants made false and/or misleading statements and/or failed to disclose that: (1) ensovibep was less effective at treating COVID-19 than defendants had led investors to believe; (2) accordingly, the U.S. Food and Drug Administration (“FDA”) was reasonably likely to require an additional Phase 3 study of ensovibep before granting the drug Emergency Use Authorization (“EUA”); (3) waning global rates of COVID-19 significantly reduced the Company’s chances of securing EUA for ensovibep; (4) as a product candidate, MP0310 (AMG 506), in development for the treatment of certain types of cancer,  was less attractive to Amgen Inc. (“Amgen”) than defendants had led investors to believe; (5) accordingly, there was a significant likelihood that Amgen would return global rights of MP0310 to Molecular Partners; (6) as a result of all the foregoing, the clinical and commercial prospects of ensovibep and MP0310 were overstated; and (7) as a result, the IPO documents and defendants’ public statements throughout the Class Period were materially false and/or misleading and failed to state information required to be stated therein. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Molecular Partners class action, go to https://rosenlegal.com/submit-form/?case_id=7548 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of IonQ, Inc. (NYSE: IONQ) between March 30, 2021 and May 2, 2022, both dates inclusive (the “Class Period”), of the important August 1, 2022 lead plaintiff deadline.

SO WHAT: If you purchased IonQ securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the IonQ class action, go to https://rosenlegal.com/submit-form/?case_id=6703 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 1, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) IonQ had not yet developed a 32-qubit quantum computer; (2) IonQ’s 11-qubit quantum computer suffered from significant error rates, rendering it useless; (3) IonQ’s quantum computer is not sufficiently reliable, so it is not accessible despite being available through major cloud providers; (4) a significant portion of IonQ’s revenue was derived from improper round-tripping transactions with related parties; and (5) as a result of the foregoing, defendants’ positive statements about IonQ’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the IonQ class action, go to https://rosenlegal.com/submit-form/?case_id=6703 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Inotiv, Inc. (NASDAQ: NOTV) between September 21, 2021 and June 13, 2022, both dates inclusive (the “Class Period”), of the important August 22, 2022 lead plaintiff deadline in the securities class action commenced by the firm.

SO WHAT: If you purchased Inotiv securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Inotiv class action, go to https://rosenlegal.com/submit-form/?case_id=6426 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 22, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose: (1) Envigo RMS, LLC (“Envigo”) and Inotiv’s Cumberland, Virginia facility (the “Cumberland Facility”) engaged in widespread and flagrant violations of the Animal Welfare Act (“AWA”); (2) Envigo and Inotiv’s Cumberland Facility continuously violated the AWA; (3) Envigo and Inotiv did not properly remedy issues with regards to animal welfare at the Cumberland Facility; (4) as a result, Inotiv was likely to face increased scrutiny and governmental action; (5) Inotiv would imminently shut down two facilities, including the Cumberland Facility; (6) Inotiv did not engage in proper due diligence; and (7) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Inotiv class action, go to https://rosenlegal.com/submit-form/?case_id=6426 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

Nyxoah to Present at the Canaccord Genuity 42^nd Annual Growth Conference

Mont-Saint-Guibert, Belgium – July 27, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will present at the Canaccord Genuity 42^nd Annual Growth Conference, which will take place in Boston, Massachusetts, from August 8 to 11, 2022.

Olivier Taelman, Nyxoah’s Chief Executive Officer, is scheduled to present a corporate update on Wednesday, August 10, 2022, at 3:30pm EDT. A webcast of the presentation will be available on the Events section of Nyxoah’s Investor Relations website. The Company will also be available for 1×1 meetings with institutional investors attending the event.

Nyxoah’s updated Investor Presentation can be accessed on the Shareholder Information section of the Company’s Investor Relations page.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com
+1 917 749 1494

Attachment

• ENGLISH_Canaccord Growth Conference PR_FINAL